ArticleJournal of medical case reports2026
Fulminant type 1 diabetes mellitus induced by tislelizumab in a patient with lung adenocarcinoma: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlthough immune checkpoint inhibitor-related endocrine adverse reactions are common in clinical practice, fulminant type 1 diabetes induced by tislelizumab remains rare. CASE PRESENTATION: A 68-year-old Asian female patient was diagnosed with stage IV BRAF V600E-mutant lung adenocarcinoma via pleural biopsy in August 2020 and initially treated with dabrafenib and trametinib. In March 2023, she started treatment with tislelizumab owing to a new metastasis in the left lower lung. On 20 May 2024, the patient was admitted to the hospital with a 3-day history of the sudden onset of dry mouth, polydipsia, and polyuria, accompanied by mild nausea and vomiting. Laboratory examination results showed hyperglycemia, ketosis, and mild metabolic acidosis, but HbA1c was mildly elevated at 7%. The C-peptide release test indicated severe insulin deficiency. She was diagnosed with fulminant type 1 diabetes, treated with intravenous insulin and fluid resuscitation, and discharged. A total of 6 months after discontinuing tislelizumab, her pancreatic function had not recovered.
conclusionTislelizumab can induce fulminant type 1 diabetes via immune-mediated mechanisms. Proactive monitoring of fasting glucose, HbA1c, and islet function is essential for patients with cancer receiving tislelizumab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.